New research published in Scientific Reports finds that cannabidiol (CBD) may play a significant role in reducing early-stage inflammation tied to obesity by altering how inflammatory lipid compounds accumulate in body fat.
The study was conducted by researchers from Vilnius University and the Medical University of Białystok using a rat model designed to mimic obesity-induced inflammation.
Researchers fed rats either a high-fat diet or a control diet and then administered CBD or a placebo. They focused on two types of fat tissue: subcutaneous adipose tissue (SAT), located beneath the skin, and visceral adipose tissue (VAT), which surrounds internal organs and is more strongly associated with metabolic disease.
Using gas–liquid chromatography and protein analysis techniques, the team examined how CBD influenced lipid fractions that serve as precursors to inflammation, along with the enzymes and cytokines involved in inflammatory pathways.
The results showed that CBD had a broad impact on visceral fat. In rats fed a high-fat diet, CBD reduced the accumulation of all lipid fractions in VAT. In SAT, the effect was more selective, with reductions observed primarily in free fatty acids and diacylglycerol. CBD also lowered levels of arachidonic acid, a key building block for inflammatory signaling molecules, and reduced the expression of enzymes responsible for producing lipid precursors of inflammation in both fat depots.
Although CBD influenced both types of adipose tissue, the changes were more pronounced in visceral fat, the tissue most closely tied to insulin resistance, cardiovascular risk, and metabolic disease.
The researchers conclude that CBD’s ability to modify lipid metabolism in adipose tissue may help blunt the inflammatory processes associated with obesity, particularly in visceral fat where the risk of metabolic complications is greatest.
Sponsored
